A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390 on ClinicalTrials.gov · last registry update 2026-10-08
An unusually large phase 3: 7,140 participants, more than double the 424 typical for the stage. Due to report August 2031, alongside 3 other tracked readouts that quarter. Primary outcome, as filed: Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for cardiovascular disease and chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 7,140
- Started
- 2025-12-01
- Primary completion
- 2031-08 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events
Conditions studied
Atherosclerosis Cardiovascular Disease · Chronic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.